Vera Therapeutics (VERA) – Investment Analysts’ Recent Ratings Updates

Vera Therapeutics (NASDAQ: VERA) has recently received a number of price target changes and ratings updates:

• 7/8/2026 – Vera Therapeutics had its price target raised by TD Cowen from $73.00 to $78.00. They now have a “buy” rating on the stock.
• 7/8/2026 – Vera Therapeutics had its price target raised by Guggenheim from $56.00 to $76.00. They now have a “buy” rating on the stock.
• 7/8/2026 – Vera Therapeutics was given a new $125.00 price target by Needham & Company LLC.
• 7/8/2026 – Vera Therapeutics had its price target raised by Wedbush from $35.00 to $43.00. They now have a “neutral” rating on the stock.
• 7/8/2026 – Vera Therapeutics had its price target raised by HC Wainwright from $110.00 to $125.00. They now have a “buy” rating on the stock.
• 7/7/2026 – Vera Therapeutics had its price target raised by Bank of America Corporation from $65.00 to $70.00. They now have a “buy” rating on the stock.
• 6/2/2026 – Vera Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $60.00 price target on the stock.
• 6/2/2026 – Vera Therapeutics had its “outperform” rating reaffirmed by William Blair.
• 6/2/2026 – Vera Therapeutics had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $90.00 price target on the stock.
• 6/2/2026 – Vera Therapeutics had its “buy” rating reaffirmed by TD Cowen.
• 5/15/2026 – Vera Therapeutics was given a new $91.00 price target by Evercore Inc.

Insider Activity

In other news, CEO Marshall Fordyce sold 46,250 shares of Vera Therapeutics stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total value of $1,956,375.00. Following the completion of the transaction, the chief executive officer owned 151,994 shares in the company, valued at approximately $6,429,346.20. The trade was a 23.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 106,201 shares of company stock valued at $4,348,762. 15.90% of the stock is owned by company insiders.

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.